Navigation Links
Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
Date:6/21/2010

QUEBEC CITY, June 21 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has completed its previously announced registered direct offering of US$12.1 million of units comprised of common shares and common share purchase warrants to certain institutional investors. Net proceeds from this offering, after deducting placement agent fees and other offering expenses total approximately US$11.3 million. All of the securities were offered pursuant to an effective shelf registration statement. Proceeds from the transaction will be used to fund the Company's AEZS-108, AEZS-112 and AEZS-130 programs and for other general corporate and working capital purposes.

Proceeds received in connection with the Company's previous registered direct offering, completed on April 20, 2010, have been and are being used primarily in connection with perifosine, the Company's lead oncology compound that is being developed in collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) ("Keryx"), following various positive developments announced with respect to perifosine during the first quarter of 2010.

Dr. Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris stated: "These recent financings, combined with our reduced burn-rate, provide us with a solid financial position to pursue our drug development programs. Our main focus will be on advancing, in collaboration with our partner Keryx, the current Phase 3 trials with perifosine for multiple myelom
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
2. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
3. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
4. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
5. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
6. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
8. AEterna Zentaris Announces Appointment of New Board Member
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 Two new educational webinars hosted by ... for ALS research and how the pharmaceutical industry can make ... Bucket Challenge: Where Does the ALS Money Go? , Featuring ... 2014, Time: 1:30pm ET, Register to attend , ... Merit Cudkowicz, Julianne Dorn Professor of Neurology at Massachusetts General ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/21/2014)... , Todd Martensen ... Mariano Rodríguez es elegid vicepresidente senior de desarrollo empresarial ... en marcha para comenzar de forma rápida la comercialización de ... aprobación en Europa   , KLOX ... los siguientes nombramientos: Todd Martensen ha ...
(Date:11/21/2014)... Palo Alto, Calif. (PRWEB) November 20, 2014 ... (CHI), a nonprofit, public policy research organization representing ... and pharmaceutical firms, and PwC US ... other states in life sciences industry growth. The ... and 2013. The 2015 California Biomedical Industry ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4
... Promises to Revolutionize Food Processing, ... ENW) ("EnWave" or "the Company") today announced that ... continuous nutraREV(TM) food dehydration equipment to CAL-SAN Enterprises, ... largest blueberry producers. With this sale, EnWave has ...
... of "In the Zone for UC" Campaign, Centocor Ortho ... Colitis Foundation of America for Each Point Pisani Scores ... Ortho Biotech Inc. announced today a partnership with professional ... colitis (UC) and funding to support continued education and ...
... Colo., March 2 Accera, Inc., ... nervous system (CNS) diseases, today launched Axona(TM) in ... is a first-in-class medical food for the clinical ... mild-to-moderate Alzheimer,s. Dispensed by prescription, it targets the ...
Cached Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4
(Date:11/15/2014)... , Nov. 13, 2014  While we may still ... Doctor McCoy used in "Star Trek" to gain instant access ... designed to work with smartphones and tablets for monitoring and ... the healthcare world. This may seem a tad Orwellian to ... to adopt some of these technological opportunities into their healthcare ...
(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... NEW ... uplinks from satellite transmitters fitted on penguins, albatrosses, sea lions, and ... have released the first-ever atlas of the Patagonian Sea a ... ...
... CORVALLIS, Ore. An accidental discovery in a laboratory ... over thousands of years has absorbed the energies of ancient ... the creation of a near-perfect blue pigment. Through ... sought inorganic compounds that could be used to paint things ...
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch ... DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and ... which detects DNA damage within seconds, activates the transcription ... triggers a survival program, which blocks programmed cell death. ...
Cached Biology News:Penguins and sea lions help produce new atlas 2Accidental discovery produces durable new blue pigment for multiple applications 2How cells tolerate DNA damage -- start signal for cell survival program identified 2How cells tolerate DNA damage -- start signal for cell survival program identified 3
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD14+ monocytes, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Biology Products: